VERISMO THERAPEUTICS
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.
VERISMO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2020-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.verismotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
215-989-4225
Email Addresses:
[email protected]
Total Funding:
40 M USD
Technology used in webpage:
Euro GoDaddy
Similar Organizations
Amber Therapeutics
Amber Therapeutics develops the next-generation of bioelectrical therapies.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Catalym
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Clarapath
We are a medical robotics company developing the SectionStar, a platform to mimic the human histotechnician.
Eyebiotech
Eyebiotech is a privately held ophthalmology biotechnology company.
Headspace Health
Headspace is a digital health platform that provides guided meditation sessions and mindfulness training.
JOGO Health
JOGO Health is a biotech company focused on digital therepeutics for neuromuscular conditions.
Q Bio
On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
Rona Therapeutics
Rona Therapeutics is a RNA therapeutics platform enabling discovery and development of modular and programmable RNA medicines.
Current Employees Featured
Founder
Investors List
DongKoo Bio&Pharma
DongKoo Bio&Pharma investment in Seed Round - Verismo Therapeutics
Hong Leong Bank
Hong Leong Bank investment in Seed Round - Verismo Therapeutics
BRV Capital Management
BRV Capital Management investment in Seed Round - Verismo Therapeutics
Key Employee Changes
Official Site Inspections
http://www.verismotherapeutics.com Semrush global rank: 13.24 M Semrush visits lastest month: 78
- Host name: 245.105.62.166.host.secureserver.net
- IP address: 166.62.105.245
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Verismo Therapeutics"
Verismo Therapeutics: KIR-CAR T Cell Therapy for Solid Tumors
Verismo Therapeutics is pioneering CAR T cell therapy for the treatment of solid tumors. This paradigm-shifting technology features a unique KIR-CAR construct that has been proven to …See details»
Verismo Therapeutics - LinkedIn
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic...See details»
Verismo Therapeutics - Crunchbase Company Profile
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. View contacts for Verismo Therapeutics to access new leads and connect with decision-makers.See details»
Contact Us - Verismo
Verismo Therapeutics is pioneering CAR T-cell therapy for the treatment of solid tumors through its revolutionary KIR-CAR platform technology. Whether you want to join our team, learn more …See details»
Platform - Verismo Therapeutics: Revolutionizing KIR-CAR Therapy
Verismo Therapeutics is pioneering CAR T cell therapy for the treatment of solid tumors through its revolutionary KIR CAR platform technology.See details»
Verismo Therapeutics - PitchBook
Developer of cancer therapeutics designed to improve persistence and efficacy against solid tumor models.See details»
Verismo Therapeutics - Overview, News & Similar companies
Verismo Therapeutics contact info: Phone number: (215) 989-4225 Website: www.verismotherapeutics.com What does Verismo Therapeutics do? Verismo Therapeutics is …See details»
Verismo Therapeutics - Craft
Verismo Therapeutics is a company that develops a KIR-CAR platform for cancer treatment. Its technology is based on chimeric antigen receptors (CAR) T-cell therapy for solid tumors …See details»
Verismo Therapeutics, Inc., Enters into Master Translational …
Feb 14, 2022 · Verismo is the only company developing the KIR-CAR platform, a modified NK-like receptor designed to drastically improve CAR-T cell therapy persistence and efficacy against …See details»
Verismo Therapeutics Receives IND Clearance from the FDA for …
May 14, 2024 · Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has received a notification from the US …See details»
Team - Verismo Therapeutics: Defining a New Generation of KIR …
Verismo was founded by the inventors of Kymriah™, the first-ever FDA-approved CAR T cell therapy. This same team saw an opportunity to overcome the limitations found in first …See details»
Verismo Therapeutics Announces $7 Million Pre-Series A with
Feb 28, 2023 · Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023. Verismo is the only company …See details»
Join Us - Verismo
Verismo is transforming the treatment of solid tumors using nature-inspired multichain receptors. If you’re looking for a rewarding career experience fueled by cutting-edge research and …See details»
Verismo Therapeutics Announces Research Partnership with the …
PHILADELPHIA, June 21, 2022 /PRNewswire/ -- Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T …See details»
Verismo Therapeutics Announces $17 million in a Second Pre …
PHILADELPHIA, July 18, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today …See details»
Verismo Therapeutics Receives IND Clearance from the FDA for …
May 14, 2024 · Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy …See details»
Pipeline - Verismo Therapeutics: Advancing the CAR 2.0 Therapy
The lead pipeline is currently under investigation in the First-in-Human Phase 1 Clinical Trial. Advancing the CAR 2.0 Therapy Through the Clinical Trial Milestones and SynKIR™ has …See details»
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV …
Feb 28, 2023 · Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023. Verismo is the only company …See details»
Media - Verismo Therapeutics: Pioneering CAR T cell therapy for …
Follow Verismo Therapeutics technology featuring KIR CAR construct that has been proven to reduce T cell exhaustion & kill solid tumor models in in vivo studiesSee details»
Verismo Therapeutics Announces the Activation of its CELESTIAL …
PHILADELPHIA, Oct. 8, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology, today announced that it has …See details»